SCHEMBL16296754

SCHEMBL16296754

Bc1ccc(S(=O)(=O)NC(C)=O)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.67
TDP1 Q9NUW8 2/20 0.67
DHFR P00374 1/20 0.67
TSHR P16473 1/20 0.67
PKM P14618 2/20 0.56
POLB P06746 1/20 0.56
KDM4E B2RXH2 1/20 0.51
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
MMP1 P03956 1/20 0.46
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
MMP13 P45452 1/20 0.46
EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7541831 0.82 SMN1; SMN2 (0.69) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL5931251 0.82 SMN1; SMN2 (0.69) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL15321641 0.80 SMN1; SMN2 (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL7402304 0.80 TSHR (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL28687948 0.80 SMN1; SMN2 (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL1684446 0.80 DHFR (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
Sulfacetamide SCHEMBL40863 0.80 SMN1; SMN2 (1.00) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL7714429 0.80 POLB (0.81) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL8777213 0.80 SMN1; SMN2 (0.67) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL29238320 0.80 SMN1; SMN2 (0.67) SMN1; SMN2TDP1DHFRTSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014200885-A1 PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2014-12-18 WO disclosed